Physician profile
Mark Pithan
NPI 1184680605
$1,325.74
in general payments reported to CMS, 2019-2025
33 companies · $94.00 in 2025
The $94.00 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $144 · 2021: $73.18 · 2022: $75.68 · 2023: $248 · 2024: $112 · 2025: $94.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $313.05 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $130.20 | 2019-2022 | |
| Abbvie INC. | $86.16 | 2023-2025 | |
| Mdd US Operations, LLC | $71.57 | 2019-2023 | Xadago, Myobloc, Apokyn |
| Biogen, INC. | $65.10 | 2019-2023 | Plegridy, Vumerity, Tysabri |
| Csl Behring | $49.27 | 2019-2023 | Hizentra |
| Amneal Pharmaceuticals LLC | $40.55 | 2019-2023 | Rytary |
| Lundbeck LLC | $39.04 | 2021-2022 | |
| Eisai INC. | $35.75 | 2023-2024 | |
| Axsome Therapeutics, INC. | $35.49 | 2023 | Sunosi |
| Allergan, INC. | $35.25 | 2020-2021 | |
| Argenx US, INC. | $29.98 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $29.73 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.34 | 2023 | Gammagard |
| Mallinckrodt Enterprises LLC | $26.09 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $24.66 | 2024 | Valtoco |
| Sunovion Pharmaceuticals INC. | $23.81 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $21.99 | 2024 | |
| Emd Serono, INC. | $21.71 | 2019 | |
| Neurocrine Biosciences, INC. | $19.29 | 2023 | Ingrezza, Ongentys |
| Genentech USA, INC. | $19.27 | 2023 | Ocrevus |
| Supernus Pharmaceuticals, INC. | $19.13 | 2019 | |
| Philips North America LLC | $17.65 | 2023 | |
| Merz North America, INC. | $17.50 | 2019 | |
| Lilly USA, LLC | $15.98 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.35 | 2019 | |
| Abbott Laboratories | $14.80 | 2024 | Infinity |
| Impel Pharmaceuticals INC. | $14.56 | 2022 | |
| Genzyme Corporation | $14.42 | 2019 | |
| Acadia Pharmaceuticals INC | $13.70 | 2019 | |
| Medtronic USA, INC. | $13.42 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.54 | 2020 | |
| Portola Pharmaceuticals, LLC | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pithan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.